Charles River Laboratories vs Mettler Toledo
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Charles River Laboratories and Mettler Toledo side by side, using each one’s latest annual report. Here is what stands out:
- Mettler Toledo is the larger business, with $4.0B of revenue in fiscal 2025 against $4.0B for Charles River Laboratories.
- Mettler Toledo grew revenue faster (4.0%, against −0.9%).
- Mettler Toledo turned more of its sales into free cash flow (21.1% FCF margin, against 12.9%).
- Mettler Toledo earned a higher return on the capital invested in it (50.5%, against 0.4%).
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Charles River Laboratories
CRL
2/8
5-year growthShare count change
Mettler Toledo
MTD
6/8
Revenue growthNet marginFCF marginReturn on capitalPiotroski F-scoreNet debt / EBITDA
Side by side
Best in the row
| Latest fiscal year | CRL FY25 | MTD FY25 |
|---|---|---|
| Size | ||
| Market cap | $16.6B | $33.7B |
| Revenue | $4.0B | $4.0B |
| Free cash flow | $518M | $849M |
| Net income | −$144M | $869M |
| Growth | ||
| Revenue growth | −0.9% | 4.0% |
| 5-year growth | 6.6% | 5.5% |
| Share count change | −4.0% | −3.0% |
| Profitability | ||
| Gross margin | — | 59.4% |
| Operating margin | 0.6% | — |
| Net margin | −3.6% | 21.6% |
| FCF margin | 12.9% | 21.1% |
| Return on capital | 0.4% | 50.5% |
| Return on equity | −4.4% | — |
| Balance sheet | ||
| Net debt | $1.9B | $2.0B |
| Net debt / EBITDA | 4.5x | 1.7x |
| Dividends and buybacks | $361M | $800M |
| Valuation & quality | ||
| P/E | — | 37.6x |
| Piotroski F-score | 4 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.